AFP to Participate in Media Literacy Week Conference with the Lakmusz-HDMO Project for International Fact-Checking Day

AFP, alongside its partners in the Lakmusz-HDMO project—an initiative funded by the European Union to combat disinformation—is participating in a week-long event in Budapest to mark International Fact-Checking Day on 2 April 2025.

AFP, alongside its partners in the Lakmusz-HDMO project—an initiative funded by the European Union to combat disinformation—is participating in a week-long event in Budapest to mark International Fact-Checking Day on 2 April 2025.
03/27/2025 11:00
Quincy Data Launches Transatlantic Signal Feeds

Quincy Data, the global leader in market data technology, announces new Transatlantic Signal Feeds distributing key CME data in London, Frankfurt, and Mumbai. This data service provides insights into large trade events for key CME futures instruments, ensuring market participants receive critical trading indicators with minimal delay. The Signal Feed latency from CME in Aurora, IL to the Slough-LD4 data center in the UK is 23.x milliseconds one-way, enabling the fastest possible price discovery...

03/27/2025 11:00
SIMO, Acer, and MediaTek Expand Availability of Acer TravelMate P4 14 to Eight New Markets

SIMO, a leader in innovative connectivity solutions, in collaboration with Acer and MediaTek, proudly announces the expansion of the Acer TravelMate P4 14 (TMP414-53-G2), an Always Connected PC (ACPC) with vSIM technology built-in, into eight new international markets. As part of its global expansion, the Acer TravelMate P4 14 is now available in Spain, France, Germany, the United Kingdom, Poland, Italy, Ireland, and Switzerland, with plans to further expand into additional regions later this y...

03/28/2025 10:00
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant tre...

03/28/2025 15:12
Join the 2025 Global Challenger Innovation Contest: Driving Inclusion Through Innovation

The 10x1000 Tech for Inclusion community and next-generation corporate venture partner xcube.co launched the Global Challenger Innovation Contest 2025 at the JUMPSTARTER 2025 event in Hong Kong SAR, China, building on the success of the 2024 competition. Now in its second year, the contest continues to empower visionaries to create tech-driven solutions that promote inclusion and drive social impact. This press release features multimedia. View the full release here: https://www.businesswire.co...